

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]

Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (nintedanib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Pulmonary Fibrosis • Afiya Trust • Black Health Agency • British Lung Foundation • Equalities National Council • Muslim Council of Britain • Muslim Health Network • Pulmonary Fibrosis Trust • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association for Respiratory Technology and Physiology • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Thoracic Society • Interstitial Lung Diseases Interdisciplinary Network (ILD-IN) • Primary Care Respiratory Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Radiologists • Royal Pharmaceutical Society • Royal College of Physicians • Royal Society of Medicine • UK Clinical Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Breathing Matters • British Association for Lung Research • Cochrane Airways Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit

Provisional stakeholder list for the Health Technology Evaluation of Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]

Issue date: April 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Castle Point and Rochford CCG • NHS Camden CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the final draft guidance.

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the final draft guidance.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final draft guidance for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts